An Observational Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Non-myeloid Malignancy

Multicenter, Observational Study to Evaluate NeoRecormon Treatment in Anemic Patients Suffering From Non-myeloid Malignancy Receiving Chemotherapy

This observational, prospective, multicenter study will evaluate the treatment response rate and the safety of NeoRecormon (epoetin beta) in anemic patients with non-myeloid malignancy. In addition to NeoRecormon, patients receive chemotherapy for their malignancy. Data will be collected for 16 weeks.

Inclusion Criteria:

• Adult patients, >/=18 years of age
• Presence of solid-tumor or non-myeloid malignancy
• Patients receiving chemotherapy
• Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
• Patients require NeoRecormon

Exclusion Criteria:

• Hypersensitivity to the drug
• Uncontrolled hypertension
• Female patients if pregnant and/or lactating